The discovery of a defective gene that increases the risk of bowel cancer development will help focus screening and treatment efforts on those individuals at greatest risk. Collaborative work between researchers from the US, Finland and New Zealand has shed light on the incidence and nature of the defect, and will lead to the development of an effective screening test.Inpharmaspoke with Professor Jeremy Jass from the University of Auckland, New Zealand, on the implications of this work.